Zellweger Spectrum Disorder (ZSD): Comprehensive Research Report

1. Disease Information

Overview. Zellweger spectrum disorder (ZSD) is the most common and clinically most severe subgroup of the peroxisome biogenesis disorders (PBDs), a group of autosomal recessive conditions caused by failure to assemble functional peroxisomes. ZSD represents a single biochemical and clinical continuum — historically split into three "distinct" diagnoses (Zellweger syndrome [most severe], neonatal adrenoleukodystrophy [NALD, intermediate], and infantile Refsum disease [IRD, mildest]) that are now recognized as points along one spectrum defined by residual peroxin function (GeneReviews, NBK1448; Klouwer et al. 2015, PMID:26627182). As the GeneReviews summary states, "Zellweger spectrum disorder... spans a phenotypic continuum ranging from a severe neonatal-onset form... to a milder, later-onset form."

Key identifiers: - MONDO: MONDO:0013932 (Zellweger syndrome; related MONDO IDs exist per causal gene, e.g., PBD1A, PBD1B) - OMIM (phenotype series/individual entries — see §4 below for the full gene-keyed list): PS214100 (Peroxisome biogenesis disorder, Zellweger syndrome spectrum) - Orphanet: ORPHA:912 (Zellweger syndrome), ORPHA:79189 (Peroxisome biogenesis disorder), with related entries for NALD (ORPHA:44) and IRD - ICD-10-CM: E71.518 (Other disorders of peroxisome biogenesis); Zellweger syndrome is also sometimes captured under Q87.8 (other specified congenital malformation syndromes) - ICD-11: 5C57.0 - MeSH: D015211 (Zellweger Syndrome); C536664 (Peroxisome biogenesis disorders)

Synonyms: Zellweger syndrome; cerebrohepatorenal syndrome; peroxisome biogenesis disorder–Zellweger syndrome spectrum (PBD-ZSS); neonatal adrenoleukodystrophy (NALD); infantile Refsum disease (IRD); peroxisomal 3-oxoacyl-CoA thiolase deficiency (historically confused with, but distinct from, ZSD).

Evidence basis of curated information: The literature is a mixture of aggregated disease-level resources (GeneReviews, Orphanet, OMIM, NORD) and primary clinical cohort/registry studies (natural history studies, caregiver surveys, medical chart reviews) — i.e., largely aggregated, disease-level characterizations supplemented by individual-patient cohort data (e.g., the NIH/Kennedy Krinstitute Longitudinal Natural History Study, NCT01668186; the caregiver cross-sectional study, PMID:33335840).

2. Etiology

Disease causal factors — genetic, monogenic. ZSD is caused exclusively by biallelic pathogenic variants in one of 13 known PEX genes, which encode "peroxins" required for peroxisomal membrane biogenesis and/or peroxisomal matrix protein import. There is no known environmental, infectious, or purely mechanistic (non-genetic) cause.

Genetic risk factors (causal genes, ranked by mutation frequency in ZSD cohorts, per GeneReviews):

Table (click to expand)

Gene	HGNC symbol	Approx. % of ZSD cases	OMIM gene	Function
PEX1	PEX1	60.5%	*602136	AAA-ATPase, PEX5/PEX7 receptor recycling (with PEX6)
PEX6	PEX6	14.5%	*601498	AAA-ATPase, partner of PEX1
PEX12	PEX12	7.6%	RING-finger peroxin, matrix import
PEX26	PEX26	4.2%	Membrane peroxin, recruits PEX1/PEX6 to peroxisome
PEX10	PEX10	3.4%	RING-finger peroxin, matrix import
PEX2	PEX2	3.1%	RING-finger peroxin, matrix import
PEX5	PEX5	2.0%	PTS1 receptor
PEX13	PEX13	1.5%	Docking-complex peroxin
PEX16	PEX16	1.1%	Membrane biogenesis peroxin
PEX3, PEX19, PEX14, PEX11B	—	<1% each	Membrane biogenesis (PEX3/19/16), division (PEX11B), docking (PEX14)

Source: GeneReviews NBK1448.

Corresponding OMIM phenotype entries include PBD1A/PBD1B (PEX1, #214100/*601539), PBD2A (PEX5, #214110), PBD3A (PEX12, #614859), PBD4A (PEX6, #614862), PBD5A (PEX2, #614866), PBD6A (PEX10, #614870), PBD7A (PEX26, #614872), PBD13A (PEX13, #614887 — approximate), among others (OMIM.org).

Risk variant example — PEX1 p.Gly843Asp (c.2528G>A, rs61750420): This is the single most common ZSD-causing allele in patient cohorts (allele frequency ~0.43 among PEX1-mutant alleles per Steinberg et al. 2006), yet it is rare in the general population (gnomAD/ClinVar general-population allele frequency ≈0.00033, i.e., ~1/3000 chromosomes) (ClinVar RCV000007946). It retains ~15% of wild-type PEX1 activity in patient fibroblasts, explaining its association with the mildest end of the spectrum. Homozygosity for this hypomorphic allele produces a mild phenotype; homozygosity for the null frameshift PEX1 p.Ile700Tyrfs42 (c.2097_2098insT) produces a severe phenotype; compound heterozygosity for the two produces an intermediate* phenotype — a clean genotype–severity correlation (GeneReviews; Mild Zellweger syndrome PEX1 variants, PMC6968987).

Founder effects (population-specific risk): - French-Canadian (Saguenay–Lac-Saint-Jean, Quebec): a PEX6 founder mutation drives an incidence of ~1/12,000 births, one of the highest in the world (PMC3483250). - PEX6 founder variant also reported causing Zellweger syndrome via possible founder effect in Mixteco (Mexican indigenous) neonates (PMC10573658). - Japan's markedly lower incidence (1/500,000) is attributed to the absence of the common European PEX1 founder variants (p.Ile700Tyrfs*42 and p.Gly843Asp). - Saudi Arabia and other high-consanguinity populations report increased ZSD prevalence attributable to consanguineous unions rather than a single founder allele.

Environmental/lifestyle risk factors: None established — ZSD is a fully penetrant monogenic disease; there is no reported gene–environment interaction modulating risk of disease occurrence. (Environmental/nutritional factors, e.g., DHA status, are relevant to secondary disease severity/management, not causation — see §12.)

Protective factors: None known at the genetic-modifier level beyond residual-activity ("hypomorphic") missense alleles, which are protective relative to null alleles in a dose-dependent way but do not prevent disease. No environmental protective exposure has been described.

Gene–environment interactions: Not applicable in the causal sense; however, catabolic stress (intercurrent illness, fasting) can unmask or worsen adrenal insufficiency and hepatic decompensation in patients with residual peroxisomal function, an indirect gene-modulated environmental interaction relevant to clinical management.

3. Phenotypes

ZSD is multisystemic. Below, phenotypes are grouped by type, with suggested HPO terms, and typical onset/severity/frequency data drawn from the largest systematic sources: the Klouwer 2015 review (PMID:26627182), the 2022 scoping review/meta-analysis/medical chart review by Berendse et al., "Characterization of Severity in Zellweger Spectrum Disorder by Clinical Findings" (PMID:35741019), and the caregiver cross-sectional study (Bose et al. 2020, PMID:33335840).

Neurological

Hypotonia (HP:0001252) — near-universal in severe/neonatal presentation; present in ~72% of "intermediate" category patients in the natural-history cohort.
Seizures (HP:0001250) — 100% in severe category (n=23), 41.3% in intermediate (n=63), 16.3% in mild (n=49) — a graded, severity-defining feature.
Abnormal EEG (HP:0002353) — 100% in severe category (n=17 assessed).
Global developmental delay (HP:0001263) — 97.5% in intermediate category (n=40); present in virtually all severe patients; may be absent or mild in the mildest phenotype.
Neuronal migration defects (e.g., polymicrogyria, HP:0002126; pachygyria HP:0001302) — characteristic of the severe/neonatal form, visible on brain MRI.
Progressive leukodystrophy/demyelination (HP:0002352) — reported in a subset, more typical of the "NALD" intermediate presentation, progressive over childhood.
Peripheral neuropathy (HP:0009830) — reported in milder, longer-surviving patients.
Ataxia (HP:0001251) — in milder/longer-surviving phenotypes.

Craniofacial / Dysmorphic

Distinctive facies (HP:0001999) — flat facies, high forehead, large fontanelles, epicanthal folds — most prominent in the severe neonatal form.

Hepatic

Neonatal cholestasis/jaundice (HP:0200034 / HP:0001080).
Hepatomegaly (HP:0002240).
Abnormal liver function (HP:0001410) — 92.9% in intermediate category (n=56).
Vitamin-K-responsive coagulopathy — from fat malabsorption/cholestasis.
Progression to fibrosis, portal hypertension, esophageal varices; hepatocellular carcinoma reported in some surviving adults.

Endocrine

Adrenocortical insufficiency (HP:0000846) — reported by 45% combined prevalence of caregivers (48% living, 40% deceased) in the caregiver survey; 54.2% in the intermediate natural-history category. Often subclinical/evolving and probably underdiagnosed, especially in milder/adult-surviving patients.

Ocular

Progressive retinal dystrophy/retinopathy (HP:0000556 retinal dystrophy; HP:0000512 nystagmus is often an early sign) — "nearly all patients develop a progressive retinopathy leading to blindness"; 89.1% vision loss in intermediate category (n=55).
Cataracts (HP:0000518) — may be congenital, especially severe form.
Glaucoma (HP:0000501).

Auditory

Sensorineural hearing loss (HP:0000407) — described as "almost always present" in childhood-onset patients; a core, near-universal feature across the spectrum, worsening with age.

Skeletal

Chondrodysplasia punctata (stippled epiphyses of patellae and long bones; HP:0002694) — characteristic of the severe neonatal form.
Osteopenia/low bone density (HP:0000939).
Amelogenesis imperfecta (enamel hypoplasia of secondary teeth; HP:0000705).

Renal

Renal cortical cysts (HP:0000107) — 79% in the severe natural-history category (n=19); a common, often congenital finding.
Nephrocalcinosis/urolithiasis from elevated urinary oxalate (HP:0000121 / HP:0000787).

Cardiac

Cardiac structural abnormalities — reported in 81.3% of a small severe-category cohort (n=16) in the meta-analysis (e.g., septal defects); less systematically characterized than other organ systems.

Gastrointestinal/Growth

Feeding difficulties/failure to thrive (HP:0011968/HP:0001508) — 71.9% in intermediate category; 0% (none) in the mild category cohort — a strongly discriminating feature between severity tiers.

Functional/Behavioral (milder end of spectrum)

Independent ambulation achieved in 87.8% of mild-category patients; full-sentence speech in 71.7%.

Phenotype characteristics summary (per severity tier, from the Berendse et al. meta-analysis, PMID:35741019): - Severe: neonatal onset, near-uniform seizures/abnormal EEG, high renal cyst prevalence, mortality before age 2 in 95.7% (n=23). - Intermediate: childhood onset, high rates of developmental delay (97.5%), vision loss (89.1%), abnormal liver function (92.9%), feeding difficulty (71.9%), adrenal insufficiency (54.2%), lower but still substantial seizure rate (41.3%). - Mild: later childhood/adolescent/adult recognition, seizures in only 16.3%, no feeding difficulties, majority ambulatory and verbal, but progressive sensory (vision/hearing) impairment remains prominent even here. - Survival differed significantly across the three severity categories by log-rank test (p<0.001).

Quality-of-life impact: Combined sensory (vision + hearing) loss plus developmental delay produces major functional impact even in "mild" survivors; caregiver-reported burden is high across the spectrum (Bose et al. 2020, PMID:33335840). No ZSD-specific EQ-5D/SF-36 dataset was identified in this search; QOL data are largely qualitative/caregiver-reported rather than standardized instrument-based.

4. Genetic/Molecular Information

Causal genes: The 13 PEX genes listed in §2, all acting via loss-of-function (biallelic) mechanisms. HGNC symbols: PEX1, PEX2, PEX3, PEX5, PEX6, PEX7 (causes the biochemically related but clinically distinct RCDP1, not classic ZSD — see below), PEX10, PEX11B, PEX12, PEX13, PEX14, PEX16, PEX19, PEX26.

Variant classification/type: - Null/loss-of-function variants (large deletions, nonsense, frameshift) — associated with severe phenotype (complete absence of peroxin function). - Missense/hypomorphic variants retaining residual function (e.g., PEX1 p.Gly843Asp) — associated with milder phenotype. - Compound heterozygosity of a null + hypomorphic allele → intermediate phenotype. - Clinical severity correlates with overall genotype/residual peroxin activity rather than which specific PEX gene is mutated — i.e., genotype (allele combination), not locus identity, is the primary determinant. - A notable genetic exception to strict autosomal-recessive inheritance: the PEX6 variant p.Arg860Trp can cause disease in a functionally heterozygous state via allelic expression imbalance (unusual dominant-like mechanism reported in GeneReviews).

Allele frequency in population databases: - PEX1 p.Gly843Asp (rs61750420): gnomAD/general-population allele frequency ≈0.00033 (≈1/3000 alleles); much higher (0.43) among PEX1-mutant disease alleles specifically (ClinVar). - A 2025 population-genetics modeling study estimated PEX1-mediated ZSD births and population prevalence using allele-frequency data (see Genetics in Medicine Open, 2025) — useful for refining historical incidence estimates that likely undercount mild/undiagnosed cases.

Somatic vs. germline: ZSD is exclusively germline (constitutional) — no somatic/mosaic ZSD-associated malignancy mechanism has been described (distinct from unrelated adult hepatocellular carcinoma occasionally reported as a complication in surviving ZSD patients, which is a disease complication, not somatic PEX pathogenesis).

Functional consequences (molecular mechanism of PEX1/PEX6, illustrative): PEX1 and PEX6 are AAA-ATPases that assemble into a heterohexameric complex mediating ATP-dependent extraction and recycling of the ubiquitinated PTS1 receptor PEX5 (and PEX7, the PTS2 receptor) from the peroxisomal membrane back to the cytosol. Loss of PEX1 function traps ubiquitinated PEX5 at the membrane, blocking further rounds of matrix protein import, causing failure to form functional peroxisomes, increased pexophagy, and formation of aberrant "ghost peroxisomes" (membrane remnants devoid of matrix enzymes) (Frontiers/PMC12626956 zebrafish Pex1 model).

Modifier genes: No validated modifier genes beyond the allelic-series (residual-activity) effect described above; ATAD1 has recently been proposed as a candidate modulator of mitochondrial/peroxisomal function in ZSD models (2025 preprint, biorxiv) but is not an established clinical modifier.

Epigenetic information: No disease-specific DNA methylation/histone-modification signature for ZSD was identified in this search; this remains an unexplored area relative to other rare monogenic diseases.

Chromosomal abnormalities: ZSD is a single-gene (biallelic small-variant) disorder; no recurrent large-scale chromosomal rearrangement (aneuploidy/translocation) mechanism is implicated. Deletion/duplication (CNV) analysis of individual PEX genes is part of standard molecular diagnostic algorithms when sequence analysis alone is uninformative (GeneReviews).

5. Environmental Information

ZSD has no infectious, toxin, or lifestyle etiology — it is fully genetic. The only "environmental" considerations relevant to the disease are: - Nutritional/metabolic stress (fasting, intercurrent illness) that can precipitate acute decompensation via unmasking adrenal insufficiency or worsening hepatic dysfunction in patients with residual peroxisomal function. - Dietary DHA (docosahexaenoic acid) status, addressed therapeutically (§12) because peroxisomal dysfunction secondarily depletes endogenous DHA synthesis. No infectious agent is implicated in disease causation or exacerbation.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

Molecular trigger: Biallelic loss-of-function variant in a PEX gene (peroxin) → failure of peroxisomal membrane biogenesis (PEX3/PEX16/PEX19) or failure of the PTS1/PTS2 matrix-protein import machinery (PEX5/PEX7 receptors; PEX13/PEX14 docking complex; PEX2/PEX10/PEX12 RING-peroxin ubiquitination machinery; PEX1/PEX6/PEX26 receptor-recycling AAA-ATPase complex) (GO:0016561 protein import into peroxisome matrix, translocation; GO:0016562 receptor recycling; Reactome R-HSA-9033241 Peroxisomal protein import).
Cellular consequence: Absence of functional (import-competent) peroxisomes, or markedly reduced peroxisome number/size ("peroxisomal ghosts") → global loss of peroxisomal enzymatic function (>50 enzymes normally housed in the organelle).
Biochemical consequence (multiple parallel metabolic failures):
Failure of peroxisomal β-oxidation of very-long-chain fatty acids (VLCFA) → VLCFA accumulation in plasma and tissues (the primary diagnostic biomarker).
Failure of plasmalogen (ether phospholipid) biosynthesis (dihydroxyacetone phosphate acyltransferase / alkyl-DHAP synthase are peroxisomal, PTS2-imported enzymes) → plasmalogen deficiency in erythrocyte membranes and, critically, in myelin, since peroxisomes are the sole site of plasmalogen synthesis.
Failure of bile acid side-chain oxidation → accumulation of toxic C27 bile acid intermediates (di- and trihydroxycholestanoic acid, DHCA/THCA) → hepatotoxicity/cholestasis.
Failure of phytanic/pristanic acid α/β-oxidation → accumulation of branched-chain fatty acids.
Impaired docosahexaenoic acid (DHA) synthesis (a partially peroxisomal pathway) → DHA deficiency, particularly relevant to retina/brain membrane composition.
Elevated pipecolic acid.
Cellular/tissue consequence:
Plasmalogen/myelin deficiency + VLCFA-driven membrane lipid abnormality → impaired oligodendrocyte myelination and neuronal migration defects (GO:0007406 negative regulation of neuroblast proliferation-type processes are affected during migration; cell types: CL:0000128 oligodendrocyte, CL:0000031 neuroblast/radial glia during migration).
Hepatotoxic bile-acid intermediates + VLCFA accumulation → hepatocyte (CL:0000182) injury, cholestasis, and progressive fibrosis (feeds a fibrotic-response-type mechanism in the liver).
VLCFA incorporation into complex membrane lipids of multiple cell types (retinal photoreceptors [CL:0000210], cochlear hair cells [CL:0000202], adrenal cortical cells [CL:1000477 / CL:0002499], renal tubular/podocyte-adjacent epithelium contributing to cyst formation) → activation of inflammatory signaling, oxidative stress, and cell dysfunction/death in each of these tissues.
Mitochondrial dysfunction: recent work shows mislocalized peroxins insert into mitochondria and disturb cristae structure directly, and mitochondrial dysfunction/oxidative stress/excess ROS are increasingly recognized as a secondary, convergent mechanism contributing to neurotoxicity alongside the primary lipid-metabolism defects (EMBO Reports, "The biochemical basis of mitochondrial dysfunction in ZSD"; PMC10652488, MAPK activation & impaired autophagy in ZSD/X-ALD).
Impaired autophagy and abnormal MAPK pathway activation have been reported in patient-derived cells, suggesting broader proteostasis/signaling disruption beyond lipid metabolism alone.
Organism-level manifestation: The combined effect of (a) neuronal migration/myelination failure, (b) hepatocellular injury, (c) adrenocortical dysfunction, (d) sensory (retinal/cochlear) degeneration, and (e) skeletal mineralization defects (chondrodysplasia punctata) produces the multisystem clinical phenotype described in §3, with severity determined by the degree of residual peroxin/peroxisome function.

Suggested GO terms (biological process): GO:0016561 (protein import into peroxisome matrix, translocation), GO:0016562 (receptor recycling), GO:0044721 (substrate release), GO:0006635 (fatty acid beta-oxidation), GO:0006654 (phosphatidic acid biosynthetic process, upstream of plasmalogen synthesis), GO:0042760 (very-long-chain fatty acid catabolic process), GO:0007041 (lysosomal transport — for the secondary autophagy defect), GO:0006979 (response to oxidative stress).

Suggested CL terms (cell types): CL:0000182 (hepatocyte), CL:0000128 (oligodendrocyte), CL:0000210 (photoreceptor cell), CL:0000202 (auditory hair cell), CL:0002499 (adrenal cortex cell) or CL:1000477, CL:0000646 (basal cell / renal tubular epithelial cell as relevant to cyst formation), CL:0000138 (chondrocyte, relevant to chondrodysplasia punctata).

Suggested UBERON terms (see §7).

Molecular profiling / omics: Lipidomic (plasmalogen/VLCFA) and to a lesser extent transcriptomic/proteomic profiling of patient fibroblasts and animal-model tissues have been used to characterize disease mechanism (e.g., mouse retinal pigment epithelium lipidomics in the PEX1-p.Gly844Asp model, biorxiv 2024); no large-scale human single-cell or spatial transcriptomic ZSD atlas was identified in this search — this remains a data gap relative to other rare disease areas.

7. Anatomical Structures Affected

Organ level: - Primary: liver (UBERON:0002107), brain/CNS (UBERON:0000955), adrenal gland (UBERON:0002369), eye/retina (UBERON:0000966 / UBERON:0000970), inner ear/cochlea (UBERON:0001846), kidney (UBERON:0002113), skeleton — long bones and patella (UBERON:0002438 femur; UBERON:0011595 patella). - Secondary/complications: cardiovascular system (structural cardiac anomalies), teeth (enamel — amelogenesis imperfecta), skin (occasionally), gastrointestinal tract (feeding dysfunction as a downstream neuro-motor consequence). - Body systems involved: nervous, hepatobiliary, endocrine, sensory (visual, auditory), skeletal, renal, and — to a lesser, secondary extent — cardiovascular.

Tissue and cell level: - Hepatocytes (CL:0000182) — cholestasis, steatosis, fibrosis. - Oligodendrocytes/myelin (CL:0000128) — leukodystrophy in the intermediate/progressive forms. - Neurons undergoing migration (radial glia-guided cortical neuroblasts) — neuronal migration defects (polymicrogyria/pachygyria). - Retinal photoreceptors and RPE (CL:0000210; CL:0002586 retinal pigment epithelial cell) — progressive retinopathy. - Cochlear hair cells (CL:0000202) — sensorineural hearing loss. - Adrenal cortical cells (zona fasciculata/reticularis) — adrenal insufficiency. - Chondrocytes of the epiphyseal growth plate — chondrodysplasia punctata. - Renal tubular epithelium — cortical microcysts.

Subcellular level (GO Cellular Component): - Peroxisome (GO:0005777) and peroxisomal membrane (GO:0005778) — the primary organelle defect. - Peroxisomal matrix (GO:0005782). - Secondary mitochondrion (GO:0005739) involvement via peroxin mislocalization and cristae disruption. - Endoplasmic reticulum contribution to peroxisomal membrane biogenesis (pre-peroxisomal vesicle origin), relevant to PEX3/PEX16/PEX19 mechanism.

Localization/laterality: Disease manifestations are bilateral/symmetric and systemic — no lateralization pattern is described (consistent with a metabolic, non-focal-lesion disease process).

8. Temporal Development

Onset: - Severe (classic "Zellweger syndrome"): congenital/neonatal onset — symptomatic at birth or within the first days of life. - Intermediate ("NALD"): infantile/early childhood onset. - Mild ("IRD" and beyond): later childhood, adolescent, or even adult recognition — onset pattern is insidious, often first suspected because of progressive sensory (vision/hearing) decline rather than an acute neonatal presentation.

Progression: - Severe form: rapid, uniformly fatal — median survival well under 1 year (mortality before age 2 in 95.7% of a severe natural-history cohort, PMID:35741019). - Intermediate form: progressive but slower — developmental delay, progressive vision/hearing loss, evolving hepatic and adrenal dysfunction over years; ~77% of children who survive the first year with a "non-progressive" trajectory reach school age (GeneReviews). - Mild form: slowly progressive, dominated by sensory (retinal, cochlear) degeneration over years-to-decades; cognition and mobility may remain largely preserved into adulthood, though hearing/vision loss is essentially universal and progressive even here. - Disease course is best described as chronic and progressive across the spectrum, with the rate of progression (not the presence of progression) distinguishing severity tiers; it is not classically relapsing-remitting.

Patterns: - No spontaneous remission is described; symptomatic/supportive treatments (e.g., cholic acid for cholestasis) can produce biochemical and some clinical improvement but do not reverse the underlying peroxisomal defect. - Critical periods: the neonatal/early-infancy window is the critical period for neuronal migration (in utero/early perinatal) — meaning the most severe structural brain malformations are fixed prenatally and not amenable to postnatal intervention, whereas ongoing myelination, retinal, cochlear, hepatic, and adrenal deterioration in milder patients represent a longer therapeutic window potentially targetable by early biochemical/gene-directed intervention (rationale behind newborn-screening-driven early diagnosis efforts, §10 and §13).

9. Inheritance and Population

Epidemiology: - US incidence: ~1/50,000 live births (historical estimate, now understood to likely undercount mild/atypical cases). - Recent New York state confirmed incidence (via newborn screening-adjacent surveillance): ~1/133,000 births. - Japan: ~1/500,000 births (absence of common European PEX1 founder alleles). - Saguenay–Lac-Saint-Jean, Quebec (French-Canadian founder population): ~1/12,000 births — one of the highest reported incidences worldwide, due to a PEX6 founder mutation (PMC3483250). - A 2025 population-genetics modeling paper specifically models PEX1-mediated ZSD births and population prevalence to refine these estimates (GIM Open 2025). - Roughly ~30% of ZSD patients carry null variants (nonfunctional PEX protein) with congenital brain malformations and infant lethality; the majority (~70%) have an intermediate-to-milder phenotype from residual PEX protein function.

Inheritance pattern: Autosomal recessive for all 13 PEX genes (with the rare functional-heterozygote exception noted for PEX6 p.Arg860Trp, §4).

Penetrance: Effectively complete/full penetrance for biallelic loss-of-function genotypes; expressivity (not penetrance per se) is the major source of variability.

Expressivity: Highly variable, driven primarily by residual peroxin activity from the specific allele combination (§4), ranging from neonatal-lethal to adult-onset sensory-predominant disease.

Genetic anticipation: Not applicable — ZSD is not a repeat-expansion disorder.

Germline mosaicism: Not specifically documented as a recurring feature of ZSD in the literature reviewed; standard autosomal-recessive recurrence risk counseling (25% affected, 50% carrier, 25% unaffected per sibling of two carrier parents) applies (GeneReviews).

Founder effects: PEX1 p.Gly843Asp and p.Ile700Tyrfs*42 (European founder alleles); PEX6 founder variant (French-Canadian/Quebec, and possibly Mixteco); population-specific allele spectra explain much of the observed geographic incidence variation.

Consanguinity role: Significant contributor in high-consanguinity populations (e.g., Saudi Arabia), where ZSD (along with many other autosomal-recessive diseases) is more frequently observed due to increased homozygosity.

Carrier frequency: Not precisely established as a single population-wide number in the sources reviewed, but individual founder-allele carrier frequencies can be substantial in specific populations (e.g., the French-Canadian PEX6 founder variant).

Population demographics: - No strong sex predilection is reported (autosomal recessive disease; consistent with a ~1:1 male:female ratio). - Geographic/ethnic variation is driven by founder-allele distribution (European vs. Japanese vs. French-Canadian vs. Middle Eastern/consanguineous populations) rather than intrinsic biological sex- or ancestry-linked susceptibility beyond allele frequency effects. - Age distribution of diagnosed individuals spans neonate through adult, reflecting the full severity spectrum, though the majority of historically diagnosed cases are neonatal/infantile because biochemical screening (VLCFA) is most sensitive in that group; milder/adult cases are increasingly recognized with molecular testing and newborn screening spillover (§10).

10. Diagnostics

Biochemical/clinical laboratory tests: - Plasma/serum very-long-chain fatty acids (VLCFA) — elevated; the classic first-line screening test, though normal/equivocal in some mild cases, a key diagnostic pitfall. - Erythrocyte plasmalogen levels (RBC C16/C18 plasmalogens) — reduced. - Phytanic acid and pristanic acid — elevated. - Pipecolic acid (plasma/urine) — elevated. - Bile acid intermediates (DHCA/THCA) — elevated in plasma and urine. - C26:0-lysophosphatidylcholine (C26:0-LPC) and C26:0-carnitine — newer, more sensitive/specific dried-blood-spot biomarkers, notably validated as secondary findings from X-ALD newborn screening programs: in California's X-ALD NBS program (screening via C26:0-LPC since 2016), 9 patients screened positive for elevated C26:0-LPC between 2016–2022 who did not have X-ALD, of whom 7 were subsequently diagnosed with ZSD via biallelic PEX variants — demonstrating C26:0-LPC's utility as an incidental ZSD-detection tool within an ALD-focused screening program (2024 publication, PMC11275617; Klouwer/Waterham C26:0-LPC and C26:0-carnitine evaluation, PMID:28677031). - Plasma C24:0- and C26:0-lysophosphatidylcholines more broadly proposed as reliable biomarkers for peroxisomal β-oxidation disorders generally (PMC10910329).

Genetic testing: - Multigene PEX panel sequencing is the recommended first-tier molecular approach (rather than single-gene sequential testing), given 13 causal genes. - Sequence analysis detects ~98% of PEX1 variants; deletion/duplication (CNV) analysis captures most of the remainder. - Exome/genome sequencing is appropriate when the clinical presentation does not clearly localize to ZSD (e.g., an atypical/mild presentation overlapping with Usher syndrome or other conditions). - Diagnosis is established by biallelic pathogenic/likely-pathogenic variants in a single PEX gene in the appropriate biochemical/clinical context.

Imaging: - Brain MRI — neuronal migration defects (polymicrogyria, pachygyria) in severe neonatal form; progressive white-matter changes (leukodystrophy) in intermediate/childhood forms. - Renal ultrasound — cortical microcysts. - Skeletal radiography — chondrodysplasia punctata (stippled epiphyses). - Liver ultrasound/elastography (fibroscan) — for ongoing hepatic surveillance.

Functional/electrophysiologic tests: - EEG — abnormal in virtually all severe-category patients. - Audiometry — for sensorineural hearing loss surveillance (annual, per GeneReviews management recommendations). - Electroretinography (ERG) — documents progressive retinal dystrophy.

Biopsy/pathology: Historically, cultured skin fibroblasts were used for biochemical complementation/functional studies (peroxisome import assays, immunofluorescence for peroxisomal marker proteins) — now largely supplanted by molecular sequencing but still useful for variant functional characterization (e.g., confirming pathogenicity of novel PEX1/PEX13 missense variants).

Clinical diagnostic criteria: No formal DSM/ICD-style operational criteria beyond the recognized triad of biochemical abnormality + compatible clinical phenotype + confirmatory biallelic PEX genotype (GeneReviews-based diagnostic algorithm).

Differential diagnosis: - Neonatal hypotonic/dysmorphic infant: trisomy 21, Prader-Willi syndrome, congenital myopathies (spinal muscular atrophy, congenital myotonic dystrophy type 1, X-linked myotubular myopathy, multiminicore myopathy). - Later/milder presentation (progressive sensory loss + mild developmental delay): Usher syndrome types I/II, Leber congenital amaurosis, Cockayne syndrome, other congenital leukodystrophies — importantly, "mild forms of PBD can be a differential diagnosis of Usher syndrome," and comprehensive mutation screening including PEX genes is recommended in patients with combined cognitive/visual/hearing impairment of uncertain cause (search synthesis; GeneReviews). - Distinct related peroxisomal disorders that must be distinguished biochemically/molecularly: rhizomelic chondrodysplasia punctata type 1 (RCDP1, PEX7) — a peroxisomal assembly defect restricted to PTS2-pathway matrix proteins (AGPS, PHYH), with a biochemically, cellularly, and clinically distinct phenotype from classic ZSD, despite shared plasmalogen deficiency; X-linked adrenoleukodystrophy (ABCD1) — a peroxisomal transporter (not biogenesis) defect causing VLCFA accumulation without global peroxisome loss.

Screening: - Newborn screening: ZSD is not yet a primary RUSP (Recommended Uniform Screening Panel) condition in the US, but is being incidentally detected via X-ALD newborn screening (C26:0-LPC), an important and expanding secondary-finding pathway (California data above). - Carrier/prenatal/preimplantation genetic screening: Offered to at-risk families once biallelic familial variants are known; prenatal diagnosis is possible by DNA testing (if variants known) or biochemical testing in cultured amniocytes/chorionic villi (if biochemical defect previously confirmed in an affected relative's fibroblasts). Preimplantation genetic diagnosis for Zellweger syndrome has been reported (ScienceDirect PGD reference).

11. Outcome/Prognosis

Survival and mortality: - Severe form: mortality before age 2 in 95.7% of a natural-history cohort (n=23); classically described as death within the first year of life without significant developmental progress. - Intermediate and mild forms: substantially better survival; ~77% of children surviving the first year with a non-progressive course reach school age (GeneReviews). Survival differences across severe/intermediate/mild categories were statistically significant (log-rank p<0.001) in the largest meta-analysis/chart-review study (PMID:35741019). - Some mildly affected individuals survive into adulthood, though with progressive sensory deficits and other systemic complications (Klouwer 2015 "adulthood" cohort, PMC4710674).

Morbidity/functional outcomes: - Even among longer-surviving (intermediate/mild) patients, near-universal progressive vision and hearing loss is the dominant chronic morbidity. - Developmental delay is common in intermediate disease (97.5%) but much less so (16.3% seizure rate as a proxy) in mild disease, where most patients achieve independent ambulation (87.8%) and full-sentence speech (71.7%). - Adrenal insufficiency, if undiagnosed, poses an ongoing acute-decompensation/mortality risk across the spectrum and is likely underdiagnosed in adolescents/adults. - Hepatic disease can progress to fibrosis/portal hypertension in surviving patients; hepatocellular carcinoma has been reported as a rare late complication in adults.

Complications: Recurrent infections/aspiration (from hypotonia/feeding dysfunction), fractures (from osteopenia), bleeding (vitamin-K-responsive coagulopathy from cholestasis), adrenal crisis, progressive blindness/deafness.

Prognostic factors: The single strongest prognostic determinant is genotype/residual peroxin activity (null vs. hypomorphic allele combination), which directly predicts which severity tier (and hence survival/functional trajectory) a patient falls into (§4, §9).

12. Treatment

There is no disease-modifying/curative therapy approved for ZSD; management is supportive/symptomatic, organ-system-directed, with active experimental gene-therapy research.

Pharmacotherapy: - Cholic acid (Cholbam™, FDA-approved for bile acid synthesis disorders including peroxisomal disorders) — oral primary bile acid that restores physiologic feedback inhibition on hepatic bile-acid synthesis, thereby suppressing production of hepatotoxic C27 bile-acid intermediates. Clinical trials/case series show reduced AST/ALT, reduced plasma/urinary bile-acid intermediates, improved weight gain, and improved survival in treated patients, though caution is needed in advanced liver disease due to potential hepatotoxicity of the therapy itself in that setting (PMID:27469511; long-term case reports in Case Reports in Gastroenterology). A long-term personalized-dosing safety study is ongoing (planned through Dec 2027). - Docosahexaenoic acid (DHA) supplementation — rationale: peroxisomal DHA-synthesis deficiency. A randomized, double-blind, placebo-controlled trial (100 mg/kg/day, 50 patients enrolled) found DHA supplementation did not reduce C26:0 levels and had inconsistent effects on visual outcomes, despite earlier small-cohort reports suggesting improved muscle tone/visual function in newborns (PMC3013498; PMID:8729110). Net evidence is not strongly supportive of DHA as an effective disease-modifying agent, though it remains used empirically in some clinical settings. - Betaine — investigated in a clinical trial context for peroxisome biogenesis disorders (NCT01838941), rationale/results not detailed in sources reviewed here. - Anti-seizure medications — standard symptomatic management for the seizure phenotype. - Glucocorticoid/mineralocorticoid replacement — for confirmed adrenal insufficiency. - Fat-soluble vitamin supplementation (A, D, E, K) — for malabsorption secondary to cholestasis. - Bisphosphonates/vitamin D — considered for osteopenia management.

Advanced/experimental therapeutics (gene therapy — active research, not yet clinically approved): - AAV8-mediated PEX1 gene augmentation (retinal-directed) in the PEX1-p.Gly844Asp mouse model improved visual function, retinal structure/response, and biochemical metabolites — "the first testing of gene therapy to treat a peroxisome biogenesis disorder," providing proof-of-concept for gene-augmentation approaches; this program had progressed enough by 2024 to attract venture investment and move toward clinical translation (Mol Ther Methods Clin Dev, PMC8516995; scientist.com webinar). - In vivo gene editing (CRISPR-based correction of a PEX1 mutation) — a 2025–2026 preclinical program corrected the disease-causing mutation in mouse models and human patient cells, returning liver tissue to near-normal function; this used the same base-editing/gene-editing platform later adapted for the high-profile "Baby KJ" personalized gene-editing case reported in 2025, and researchers are now exploring delivery modalities that extend beyond liver to the CNS for broader multi-organ benefit (hearing, vision) (JAX news, April 2026; biorxiv 2026 preprint). - No RNA-based (ASO/siRNA), cell-therapy, or approved small-molecule targeted therapy for ZSD itself was identified in this search (as distinct from the ASO-based therapies used in unrelated peroxisomal-transporter disease X-ALD, which is molecularly distinct — ABCD1, not a PEX biogenesis gene).

Surgical/interventional: Cataract extraction; gastrostomy tube placement for feeding difficulty/dysphagia; occasional orthopedic intervention for skeletal complications.

Supportive/rehabilitative care: - Hearing aids/cochlear implantation consideration for sensorineural hearing loss. - Physical, occupational, and speech therapy. - Nutritional support/feeding therapy. - Dental surveillance/intervention for amelogenesis imperfecta (every 6 months per management guidelines).

Surveillance schedule (per GeneReviews management recommendations): growth/nutrition at each visit; annual audiology; annual ophthalmology; annual liver function tests + ultrasound/fibroscan; ACTH/cortisol by age 1 year then annually; dental every 6 months; annual urine oxalate-to-creatinine ratio; head MRI as clinically indicated.

Suggested MAXO terms: MAXO:0000004 (surgical procedure — cataract extraction), MAXO:0000011 (physical therapy), MAXO:0000088 (dietary intervention — DHA/vitamin supplementation), MAXO:0000950 (supportive care); pharmacotherapy of cholic acid would use the generic NCIT:C15986 (Pharmacotherapy) treatment-term pattern with therapeutic_agent bound to the specific compound (cholic acid; CHEBI:16359).

Treatment strategy/personalized medicine: Management is explicitly organ-system-by-organ-system and severity-tiered — i.e., a personalized surveillance/intervention algorithm keyed to where a given patient falls on the severity spectrum, rather than a single uniform treatment algorithm, reflecting the absence of a disease-modifying therapy.

13. Prevention

Primary prevention: Not possible in the traditional sense (no modifiable risk factor); the only "primary prevention" avenue is reproductive, via carrier screening and reproductive decision-making (prenatal diagnosis, preimplantation genetic diagnosis) in families with a known PEX pathogenic variant, or in populations with elevated carrier frequency (e.g., pre-conception expanded carrier screening in consanguineous populations, as illustrated by an Afghan-descent consanguineous cohort study referenced in this search — PMC12167801).
Secondary prevention (early detection): Incidental detection through X-ALD newborn screening (C26:0-LPC, C26:0-carnitine) is an emerging, real-world secondary-prevention pathway that identifies ZSD before overt clinical presentation, enabling earlier initiation of supportive therapy (cholic acid, endocrine/audiology/ophthalmology surveillance) and more accurate genetic counseling.
Tertiary prevention: The entire structured surveillance program described in §12 (annual audiology, ophthalmology, hepatic, endocrine, renal, dental monitoring) functions as tertiary prevention — aiming to catch and manage organ-specific complications before they cause irreversible harm (e.g., catching adrenal insufficiency before crisis, catching hearing/vision loss early enough for assistive intervention).
Genetic counseling: Recommended for affected individuals, known carriers, and at-risk relatives, covering recurrence risk (25%/50%/25% per sibling for AR inheritance), reproductive options, and prenatal/preimplantation testing availability once familial variants are known.
No immunization/vaccine strategy is applicable (non-infectious, genetic disease).
No specific environmental/public-health intervention applies beyond population-level carrier-screening programs in high-risk/consanguineous communities.

14. Other Species / Natural Disease

Taxonomy: No well-documented naturally occurring (spontaneous) Zellweger-spectrum-equivalent disease was identified in companion animals (dogs/cats) or livestock in the sources reviewed here; OMIA (Online Mendelian Inheritance in Animals) was not directly queryable in this search session, and general veterinary-genetics sources referenced in the search did not specifically document a natural PEX-gene disease in domestic species. This should be treated as absence of evidence found, not confirmed absence — a direct OMIA database query is recommended before asserting no natural animal disease exists.
Gene orthologs: PEX1, PEX6, PEX5, PEX2, PEX7, etc. are broadly conserved across vertebrates and even into yeast (where PEX gene biology was originally characterized), reflected in the extensive use of mouse, zebrafish, and even Drosophila/yeast models (below) — i.e., the mechanism is deeply evolutionarily conserved even though naturally occurring veterinary disease is not well documented.
Comparative biology: The core peroxisomal biogenesis/import pathway (PTS1/PTS2 receptors, RING-peroxin ubiquitination, AAA-ATPase recycling) is conserved from yeast to humans, which is precisely why yeast and Drosophila genetics originally defined much of PEX gene function before human disease genes were identified.
Zoonotic potential/transmission: Not applicable — ZSD is a non-transmissible monogenic disease.

15. Model Organisms

Mouse models: - Constitutive knockouts of Pex5, Pex2, and Pex11β recapitulate the severe end of the spectrum but die shortly after birth due to profound hypotonia/respiratory failure, which has historically limited postnatal disease-progression studies (Nature Genetics 1997, "A mouse model for Zellweger syndrome"). - PEX1-G844D (Gly844Asp) knock-in mouse — models the mild end of the human spectrum (analogous to the common human p.Gly843Asp hypomorphic allele) and is viable long-term, recapitulating growth retardation, fatty liver, retinopathy, cochlear hair-cell degeneration, and hearing loss — making it "a robust pre-clinical model for mild Zellweger spectrum disorder" used in longitudinal natural-history and therapeutic (AAV gene-therapy) studies (ScienceDirect longitudinal study; AAV-PEX1 gene augmentation study, PMC8516995; 2024 RPE lipidomics biorxiv; 2025 liver-disease-progression biorxiv). - A Pex7-deficient mouse series exists for the related but distinct disorder RCDP1 (not classic ZSD), correlating biochemical/neurobehavioral markers with genotype severity (PMC9310236).

Zebrafish models: - A Pex1 loss-of-function zebrafish model was recently shown to be viable (unlike the severe mouse knockouts) and to recapitulate hallmarks of ZSD, offering a tractable, higher-throughput vertebrate system for mechanistic and drug-screening studies (Frontiers in Molecular Neuroscience 2025, PMC12626956).

Invertebrate/cellular models: - Drosophila models have been used to dissect substrate-channeling effects on phospholipids and sphingolipids in peroxisomal biogenesis disorders, complementing vertebrate models for specific lipidomic mechanism questions (PMC12157166); Drosophila and mouse models have also been used to show that peroxisomal biogenesis is genetically and biochemically linked to carbohydrate metabolism (PMC5480855). - Patient-derived fibroblasts remain a standard cellular model for functional variant classification (e.g., confirming the ~15% residual activity of PEX1 p.Gly843Asp) and for studying secondary mechanisms such as MAPK pathway activation and impaired autophagy (PMC10652488). - Yeast (historically Saccharomyces cerevisiae, Pichia pastoris) was the original discovery system for most PEX genes and remains used for basic peroxin biochemistry (e.g., PEX14 phosphorylation and matrix-protein import studies).

Phenotype recapitulation and limitations: - Severe-knockout mice (Pex5/Pex2/Pex11β) faithfully model lethality and hypotonia but cannot be used to study chronic, progressive organ pathology because of neonatal death — a key model limitation. - The PEX1-G844D mouse is currently the best-characterized long-term model, closely recapitulating the human mild ZSD phenotype (hearing loss, retinopathy, liver disease) and serving as the primary preclinical platform for the AAV-gene-therapy and gene-editing programs described in §12. - The new viable zebrafish Pex1 model is positioned as a complementary, more scalable system for hallmark-recapitulation and prospective drug/gene-therapy screening. - No model fully recapitulates the entire human severity spectrum in one organism; researchers instead use different models for different severity tiers (severe knockout mice for the lethal end; PEX1-G844D mice and the new zebrafish model for the mild/intermediate end).

Model databases/resources: MGI (Mouse Genome Informatics) for Pex-gene mouse alleles; ZFIN for the zebrafish Pex1 model; FlyBase for the Drosophila peroxisomal-biogenesis lines referenced above.

Zellweger Spectrum Disorders